[go: up one dir, main page]

MX2017011562A - Conjugados de un resto de il-7 y un polimero. - Google Patents

Conjugados de un resto de il-7 y un polimero.

Info

Publication number
MX2017011562A
MX2017011562A MX2017011562A MX2017011562A MX2017011562A MX 2017011562 A MX2017011562 A MX 2017011562A MX 2017011562 A MX2017011562 A MX 2017011562A MX 2017011562 A MX2017011562 A MX 2017011562A MX 2017011562 A MX2017011562 A MX 2017011562A
Authority
MX
Mexico
Prior art keywords
conjugates
moiety
polymer
nonpeptidic
methods
Prior art date
Application number
MX2017011562A
Other languages
English (en)
Other versions
MX391071B (es
Inventor
Ping Zhang
Deborah H Charych
Benedict Kirk Peter
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MX2017011562A publication Critical patent/MX2017011562A/es
Publication of MX391071B publication Critical patent/MX391071B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan conjugados de un resto de IL-7 y uno o más polímeros hidrosolubles no peptídicos; normalmente, el polímero hidrosoluble no peptídico es poli(etilenglicol) o un derivado de éste; también se proporcionan, entre otras cosas, composiciones que comprenden los conjugados, métodos para preparar los conjugados y métodos para administrar las composiciones a un individuo.
MX2017011562A 2015-03-11 2016-03-11 Conjugados de un resto de il-7 y un polímero. MX391071B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562131634P 2015-03-11 2015-03-11
PCT/US2016/022146 WO2016145388A1 (en) 2015-03-11 2016-03-11 Conjugates of an il-7 moiety and an polymer

Publications (2)

Publication Number Publication Date
MX2017011562A true MX2017011562A (es) 2018-05-11
MX391071B MX391071B (es) 2025-03-21

Family

ID=56878892

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011562A MX391071B (es) 2015-03-11 2016-03-11 Conjugados de un resto de il-7 y un polímero.

Country Status (11)

Country Link
US (1) US20190290733A1 (es)
EP (1) EP3285799A4 (es)
JP (3) JP2018510863A (es)
KR (2) KR20250052471A (es)
CN (1) CN107405384A (es)
AU (1) AU2016228555B2 (es)
CA (1) CA2978330C (es)
IL (1) IL254389B2 (es)
MA (1) MA41957A (es)
MX (1) MX391071B (es)
WO (1) WO2016145388A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001296962A1 (en) 2000-09-29 2002-04-08 Schering Corporation Pegylated interleukin-10
NO346530B1 (no) 2006-09-28 2022-09-26 Merck Sharp & Dohme Anvendelser av pegylert interleukin-10 (PEG-IL-10) for å forebygge metastaser av kreft eller tumor i lungene.
CN106913865A (zh) 2013-04-18 2017-07-04 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
AU2014281828B2 (en) 2013-06-17 2019-05-09 Armo Biosciences, Inc. Method for assessing protein identity and stability
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
HK1248137A1 (zh) 2015-05-28 2018-10-12 阿尔莫生物科技股份有限公司 用於治疗癌症的聚乙二醇化白细胞介素-10
CA2995120A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2020121071A1 (en) * 2018-12-12 2020-06-18 Levim Biotech Llp Acylation process for preparation of n-substituted peptide
WO2022020637A1 (en) * 2020-07-22 2022-01-27 Nektar Therapeutics Il-7 receptor agonist composition and related methods and uses
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666400B2 (en) * 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
AU2002307497A1 (en) * 2001-04-23 2002-11-05 The Regents Of The University Of California Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts
JP2005525302A (ja) * 2001-11-20 2005-08-25 ファルマシア・コーポレーション 化学的に修飾されたヒト成長ホルモンコンジュゲート
EP1391513A1 (en) * 2002-08-08 2004-02-25 Cytheris IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
JP2006519170A (ja) * 2002-12-26 2006-08-24 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド サイトカイン、ケモカイン、増殖因子、ポリペプチドホルモン、およびレセプター結合活性が保存されたそのアンタゴニストのポリマー結合体
RU2437893C2 (ru) * 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
WO2009089396A2 (en) * 2008-01-08 2009-07-16 Neose Technologies, Inc. Glycoconjugation of polypeptides using oligosaccharyltransferases
MX388465B (es) * 2010-11-12 2025-03-20 Nektar Therapeutics Conjugados de un resto de interleucina-2 y un polímero.
CN102145178B (zh) * 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
WO2013020079A2 (en) * 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
EP2780361B1 (en) * 2011-11-14 2018-01-17 Emory University Conjugates of gm-csf and il-7, compositions and methods related thereto

Also Published As

Publication number Publication date
CA2978330A1 (en) 2016-09-15
AU2016228555A1 (en) 2017-08-31
IL254389B2 (en) 2023-03-01
IL254389B (en) 2022-11-01
WO2016145388A1 (en) 2016-09-15
MX391071B (es) 2025-03-21
JP2018510863A (ja) 2018-04-19
EP3285799A1 (en) 2018-02-28
JP2021091708A (ja) 2021-06-17
AU2016228555B2 (en) 2021-12-23
CA2978330C (en) 2024-01-09
JP2022163194A (ja) 2022-10-25
KR20250052471A (ko) 2025-04-18
KR20170125839A (ko) 2017-11-15
CN107405384A (zh) 2017-11-28
MA41957A (fr) 2018-02-28
US20190290733A1 (en) 2019-09-26
EP3285799A4 (en) 2018-08-08
IL254389A0 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
MX2021015492A (es) Conjugados de un resto de interleucina-15 (il-15) y un polimero.
MX2017011562A (es) Conjugados de un resto de il-7 y un polimero.
IL268888A (en) Multispecific binding proteins targeting caix, ano1, mesothelin, trop2, cea, or claudin-18.2
MX2013005363A (es) Conjugados de un resto de interleucina-2 y un polimero.
EP4295840A3 (en) Glycan polymers and related methods thereof
SG10201909805XA (en) Surface modified polymer compositions
WO2016040369A3 (en) HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
EP4620520A3 (en) Methods and compositions relating to chondrisomes
MX2016009943A (es) Composiciones de nanotribologia y metodos relacionados que incluyen nanolaminas moleculares.
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
MX382791B (es) Conjugados novedosos de glicano y uso de los mismos
MX381160B (es) Agonistas del receptor de apelina y metodos de uso.
MY166898A (en) Polymer having terminal structure including plurality of reactive solicon groups, method for manufacturing same, and use for same
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
MX376824B (es) 2,4-dihidroxi-nicotinamidas como agonistas del recepor de apelina (apj).
MX2016003922A (es) Copolimeros de silicona-polieter, adhesivos y articulos medicos que los comprenden, y metodos para elaborarlos.
EP4252681A3 (en) Implantable objects, guiding devices, and methods of use thereof
MX2013007230A (es) Sistemas de polimero.
SA518391465B1 (ar) حبة تحكم في فقد مائع أساسها بوليمر تخليقي
ZA201905895B (en) Kits and methods for preparing pathogen-inactivated platelet compositions
EP3510117A4 (en) GLYOXALATED LIGNIN COMPOSITIONS
WO2013020079A3 (en) Conjugates of an il-11 moiety and a polymer
MY181478A (en) Mixed decyl mercaptans compositions and methods of making same
MX379622B (es) Compuestos espirociclicos
MX392293B (es) Composición química de ácido hialurónico